

PRODUCT INFORMATION



Epalrestat

Item No. 15214

CAS Registry No.: 82159-09-9
Formal Name: 5Z-[(2E)-2-methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid

Synonym: ONO-2235

MF: C₁₅H₁₃NO₃S₂

FW: 319.4


Purity: ≥98%

UV/Vis.: λ_{max}: 237, 292, 390 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Epalrestat is supplied as a crystalline solid. A stock solution may be made by dissolving the epalrestat in the solvent of choice, which should be purged with an inert gas. Epalrestat is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of epalrestat in these solvents is approximately 2 and 10 mg/ml, respectively.

Epalrestat is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, epalrestat should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Epalrestat has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Epalrestat is an inhibitor of aldose reductase (IC₅₀s = 0.01 and 0.26 μM for rat lens and human placenta aldose reductase, respectively).¹ It inhibits glucose-induced sorbitol accumulation in isolated rat lens, rat sciatic nerve, and human erythrocytes (IC₅₀s = 1.5, 5, and 1.5 μM, respectively). It decreases high glucose-induced proliferation of vascular smooth muscle cells when used at a concentration of 10 nM and prevents high glucose-induced intracellular NADH/NAD⁺ increases and membrane-bound PKC activation at 100 nM.^{2,3} Epalrestat (20 and 40 mg/kg) improves motor nerve conduction velocity and decreases sorbitol content in the sciatic nerve and erythrocytes in a rat model of streptozotocin-induced diabetic neuropathy.⁴ It also prevents capillary strand formation in a rat model of diabetes-induced retinal microangiopathy when administered at a dose of 50 mg/kg.⁵

References

1. Terashima, H., Hama, K., Yamamoto, R., et al. *J. Pharmacol. Exp. Ther.* **229**(1), 226-230 (1984).
2. Yasunari, K., Kohno, M., Kano, H., et al. *Hypertension* **35**(5), 1092-1098 (2000).
3. Yasunari, K., Kohno, M., Kano, H., et al. *Arterioscler. Thromb. Vasc. Biol.* **15**(12), 2207-2212 (1995).
4. Kikkawa, R., Hatanaka, I., Yasuda, H., et al. *Diabetologia* **24**(4), 290-292 (1983).
5. Kojima, K., Matsubara, H., Mizuno, K., et al. *Nippon Ganka Gakkai Zasshi* **89**(2), 247-256 (1985).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM